Кардиоваскулярный риск у больных подагрой

Полный текст:

Список литературы

1. Барскова В.Г., Елисеев М.С., Насонов Е.Л., с соавт. Синдром инсулинорезистентности у больных подагрой и его влияние на формирование клинических особенностей болезни. Тер архив. 2004; 5:51-55.

2. Барскова В.Г., Якунина И.А., Ильиных Е.В., с соавт. К вопросу о тяжести течения женской подагры. Тер архив. Принято в печать.

3. Перова Н.В. Суммарный риск ИБС и показания к лечению гиперхолестеринемии (применение Европейских рекомендаций к российским условиям) // Кардиология. 1996. С. 49-53.

4. Перова Н.В. Суммарный риск ишемической болезни сердца и показания к лечению гиперхолестеринемий. Кардиология. 1996;3:47-53.

5. Насонова В.А., Барскова В.Г. Ранние диагностика и лечение подагры: научно обоснованное требование улучшения трудового и жизненного прогноза больных. Научно-практическая ревматология. 2004;1:5-7.

6. Аndersson K.M., Wilson W.F., Odell P.M. et al. An updated coronary risk profile - a statement for health professionals. Circulation. 1991;83:356-362.

7. Assman G., Cullen P., Schulte H. The Munster heart study (PROCAM). Eur Heart J. 1998;19(Suppl A):A2-A11.

8. Assmann G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J. 1998;19(suppl M):M8-M14.

9. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998;81:7B-12B.

10. Averina M., Nilssen O., Brenn T., et al. High cardiovascular mortality in Russia cannot be explain by the classical risk factors. The Archangelsk study 2000. Eur J Epidemiol. 2003;18:871-878.

11. Berkowitz D. Gout, hyperlipidemia and diabetes interrelationships. JAMA. 1966;197:77-80.

12. Bieber J.D., Terkeltaub R.A. On the brink of novel therapeutic options for an ancient disease. Arthr Rheum. 2004;50(8):2400-2414.

13. Borona E, Targer G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assesment of insulin sensitivity. Diabetes Care. 2000;23:57-63.

14. Bjartveit K., Foss O.P., Gjervig T., Lund-Larsen P.G. The cardiovascular disease study in Norwegian countries. Background and organization. Acta Med Scand. 1979;(suppl 634).

15. Chait A, Brunzell JD. Acquired hyperlipidemia (secondary dyslipoproteinemias). Endocrinol Metab Clin North Am. 1990;19:259-78.

16. Coronary heart disease:reducing the risk. The scientific background for primary and secondary prevention of coronary heart disease. A worldwide view. Intern. Atherosclerosis Society. Nutr Metab Cardiovasc Dis. 1998;8:205-271.

17. Dessein P.H., Stanwix A.E., Shipton E.A. et al. Dislipidemia and insulin resistance in gout: sufficiently common to be considered in the evaluation and management of every patient. III. African League Against Rheumatism (AFLAR) Conference. Cape Town, South Africa, September 1999. Cape Town: Ukenza 1999.

18. Engelhardt H.T., Wagner E.L. Gout, diabetes mellitus and obesity, a poorly recognized syndrome. South Med J. 1950;43:51-53.

19. Facchini F, Ida Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistanse to insulin-mediated glucose uptake, urinary uric acid clearance and plasma uric acid concentration. JAMA. 1991;266:3008-3011.

20. Fam AG. Gout, diet, and the insulin resistance syndrome. J Rheumatol. 2002 Jul; 29(7):1350-1355.

21. Ferranninni E., Haffner S.M., Mitchel B.D., et al. Hyperinsulinaemia:the key feature of a cardiovascular and metabolic syndrome. Diabetologia. 1991;34:416-422.

22. Gibson T., Grahame R. Gout and hyperlipidaemia. Ann Rheun Dis. 1974;33:298-303.

23. Ginter E. Cardiovascular risk factors in the former communist countries. Analysis of 40 European MONICA populations. Eur J Epidemiol. 1995;11:199-205.

24. Gordon DJ, Probstfield JL, Garrison RJ, et al High-density lipoprotein cholesterol and cardiovascular disease:four prospective American studies. Circulation. 1989;79:8-15.

25. Graham R., Scott J.T. Clinical survey of 354 patients with gout. Ann Rheum Dis. 1970;29:461-468.

26. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol. 1998;81:18B-25B.

27. Gutman A.B. Views on the pathgenesis and management of primary gout. 1971. J Bone Joint Surg. 1972;54A:357-372.

28. Haffner SM, Gonzalez C, Miettinen H. et al. A prospective analysis of the HOMA model:the Mexico City Diabetes Study. Diabetes Care. 1996;19:1138-1141.

29. Klag MJ, Ford DE, Mead LA, et al. Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med. 1993;328:313-8.

30. Kuulasmaa K., Tunstall-Pedoe H., Dobson A., et al. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA project population. Lancet. 2000;355:675-687.

31. Masanori E, Yoshiki N, Kiyoshi M,Yoshikazu H et al. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care. 1999;22:818-822.

32. Mayne J.G. Pathological study of the renal lesions found in 27 patients with gout. Ann Rheum Dis. 1956;15:61-62.

33. National Cholesterol Education Program. Third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. (Adult Treatment Panel III), NIH Pub. No. 092-5215. Bethesda, MD:National Heart, Lung, and Blood Institute, 2002.

34. Phillips NR, Havel RJ, Kane JP. Levels and interrelationships of serum and lipoprotein cholesterol and triglycerides: association with adiposity and the consumption of ethanol, tobacco, and beverages containing caffeine. Аrteriosclerosis. 1981;1:13-24.

35. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary prevention. Europ Heart J. 1998;19:1434-1503.

36. Puska P., Matilainen T., Jousilahti P., et al. Cardiovascular risk factors in the Republic of Karelia, Russia, and the North Karelia, Finland. Int J Epidemiol. 1993; 22:1048-1055.

37. Radic M.T., Valkenburg H.A., Davidson R.T. et al. Observations on the natural history of hyperuricemia and gout. I. An eighteen-year follow-up of nineteen gouty families. Am J Med. 1964;37:862-871.

38. Rodnan G.P. A gallery of gout. Arthritis Rheum. 1968;4:520-528.

39. Schaefer EJ, Lamon-Fava S, Ordovas JM, Cohn SD, Schaefer MM, Castelli WP, Wilson PWF. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res. 1994;35:871-82.

40. Seidell J. Obesity in Europe. Obes Res. 1995; Sept(3 Suppl 2):89s-93s.

41. Shalnova S., Shestov D., Ekelund L-G., et al. Blood pressure and heart rate rsponse during exercise in men and women in the USA and Russia lipid research clinics prevalence study. Atherosclerosis. 1996;122:47-57.

42. Stone NJ. Secondary causes of hyperlipidemia. Med Clin North Am. 1994;78:11741.

43. Takahashi S., Moriwaki Y., Tsutsumi Z. et al. Increased visceral fat accomulation further aggravates the risk of insulin resistance in gout. Metabolism. 2001;Apr. 50(4):393-398.

44. Vazquez-Mellado J., Garsia C.G., Vazquez S.G. et al Metabolic syndrome and ischemic heart disease in gout. J Clin Rheum. 2004;3(10):105-109.

45. Wallace, SL, Robinson, H, Masi, AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20:895.

46. Weiss T.E., Segaloff A. Gouty arthritis and Gout. Springfield, Ill, Thomas, 1959, 74.

47. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-47.

48. Wyngaarden JB, Kelley WN, eds. Gout and Hyperuricemia. London: Grune & Stratton. 1976:270-283.

Для цитирования:

Barskova V.G., Il'inykh E.V., Eliseev M.S., Zilov A.V., Nasonov E.L. Кардиоваскулярный риск у больных подагрой. Ожирение и метаболизм. 2006;3(3):40-44.

For citation:

., ., ., ., . Kardiovaskulyarnyy risk u bol'nykh podagroy. Obesity and metabolism. 2006;3(3):40-44. (In Russ.)

Просмотров: 5

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 2071-8713 (Print)
ISSN 2306-5524 (Online)